How retatrutide works: triple agonism, explained

When you eat, specialized cells in the gut release hormones into the bloodstream. Two of these — GLP-1 and GIP — are called incretins: they amplify the insulin response to food and influence how the brain registers fullness.

The natural versions of these hormones break down in minutes. The drugs in this class — semaglutide, tirzepatide, retatrutide — are engineered peptides that resist that breakdown, so they stay active for days. Once-weekly dosing is the result. [1]

Glucagon is the third hormone in the picture. Unlike the incretins, glucagon's usual job is to raise blood sugar by signaling the liver. But chronic, controlled activation of the glucagon receptor — when paired with GLP-1 and GIP-driven insulin release — appears to increase energy expenditure without raising blood sugar.

GLP-1 receptor activation does several things. In the brain, it reduces hunger signaling and lowers food reward — people eat less. In the stomach, it slows gastric emptying — people feel full longer. In the pancreas, it amplifies insulin secretion when blood sugar is elevated, without driving hypoglycemia.

This is the same mechanism that makes Ozempic and Wegovy (semaglutide) work. Retatrutide is engineered to bind the GLP-1 receptor with high potency. [1]

GIP's best-established role is amplifying insulin secretion after meals — similar to GLP-1. Beyond that, GIP appears to modulate fat metabolism, though the exact contribution to weight loss in humans is still under active investigation.

Tirzepatide established that adding GIP to GLP-1 produced larger effects than GLP-1 alone, both for weight and for HbA1c. Whether that benefit comes from GIP itself or from how the drug interacts with each receptor is debated.

Glucagon is usually thought of as a hormone that raises blood sugar. Used alone or in unbalanced combinations, glucagon activation would do exactly that. But when retatrutide binds the glucagon receptor, it does so alongside potent GLP-1 and GIP activation — which together blunt the blood-sugar effect.

The mechanistic upside is energy expenditure: glucagon-receptor activation appears to increase resting metabolic rate and promote fat utilization, particularly in the liver. The hypothesis — supported but not proven by Phase 2 data — is that this is what allows retatrutide to outperform tirzepatide on average weight loss. [2]

The likely tradeoff is the small dose-dependent increase in resting heart rate observed in trials, which is consistent with glucagon-receptor activation increasing sympathetic tone.

Retatrutide is not equipotent at all three receptors. Lilly tuned its relative activity at GLP-1, GIP, and glucagon specifically to maximize weight loss while controlling blood sugar. Too much glucagon activation relative to GLP-1/GIP would risk hyperglycemia; too little would forfeit the energy-expenditure advantage. [1]

This is why "research peptides" sold online claiming to be retatrutide are uninterpretable: identity, purity, and the specific receptor selectivity profile are not verifiable.

Like semaglutide and tirzepatide, retatrutide is a peptide modified with a fatty-acid side chain. The fatty-acid tail binds non-covalently to albumin, dramatically slowing renal clearance and pushing the half-life into the multi-day range that supports once-weekly dosing.

The peptide's amino-acid sequence is engineered to balance affinity at the three target receptors and to resist enzymatic degradation by DPP-4, the enzyme that breaks down endogenous GLP-1 within minutes.